Symbiotec Pharmalab Ltd
Thu 8/10/2026,15:59:20 | NSE : SYMBIOTEC
Data is delayed. Analysis is best done in real-time! Open a FREE Sharekhan Demat A/c in 15 mins* and continue your analysis with real-time data.
Market Data
Essential tool: analyze, trade, manage, decide.
Open
₹ 1130.00
Previous Close
₹ 1135.60
Volume
645045
Mkt Cap ( ₹ Cr)
₹ 7028.33
High
₹ 1143.00
Low
₹ 1080.70
52 Week High
₹ 1246.00
52 Week Low
₹ 934.20
Book Value Per Share
₹ 178.98
Dividend Yield
0.00
Face Value
₹ 2.00
What's Your Call?
Collective community sentiment on Symbiotec Pharmalab Ltd
Your Vote -
Buy
50.00%
Hold
0.00%
Sell
50.00%
50.00%
2 users have voted
Market Depth
How many stocks are available to buy or sell and at what prices.
Buy Order Quantity
0%
Sell Order Quantity
100%
Bid Price
Qty
0.00
0
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
0
Bid Price
Qty
1093.80
108
0.00
0
0.00
0
0.00
0
0.00
0
Bid Total
108
Option Chain
Analyzes market sentiment, predicts Symbiotec Pharmalab Ltd' movement.
NO_RECORD_FOUND
News
Media spotlight triggers stock stock attention, sentiment.
-
Symbiotec Pharmalab - Certificate under SEBI (Depositories and Participants) Regulations, 2018
-
Symbiotec Pharmalab - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
-
Symbiotec Pharmalab - General Updates
-
Symbiotec Pharmalab - General Updates
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Trading Window
-
Symbiotec Pharmalab - General Updates
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Announcement Under Regulation 30 (LODR)-Symbiotec Pharmalab Limited Receives Establishment Inspection R
-
Symbiotec Pharmalab - Analysts/Institutional Investor Meet/Con. Call Updates
-
Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Earnings Call Transcript
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Symbiotec's Wholly Owned Subsidiary Knovea Pharmaceutical Enters Into Strategic Commercialization Agre
-
Symbiotec Pharmalab - Analysts/Institutional Investor Meet/Con. Call Updates
-
Symbiotec Pharmalab - Copy of Newspaper Publication
-
Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome
-
Symbiotec Pharmalab Q1 net profit up 5.62% at Rs 47.01 cr
-
Symbiotec Pharmalab - Press Release
-
Symbiotec Pharmalab - Investor Presentation
-
Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Press Release / Media Release
-
Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Investor Presentation
-
Symbiotec Pharmalab - Outcome of Board Meeting
-
Symbiotec Pharmalab - Results - Financials For Quarter Ended Jun 30, 2026
-
Symbiotec Pharmalab - Outcome of Board Meeting
-
Symbiotec Pharmalab - Board Meeting Outcome for Outcome Of The Board Meeting Of The Company Held On Monday, September 21, 202
-
Symbiotec Pharmalab - Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
-
Symbiotec Pharmalab - Board Meeting Intimation for Prior Intimation Of The Meeting Of The Board Of Directors Of Symbiotec Pha
-
Symbiotec Pharmalab - Updates
-
Symbiotec Pharmalab - Update On Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition O
-
Symbiotec Pharmalab has submitted to BSE the Shareholding Pattern for the Period Ended August 31, 2026
-
Symbiotec Pharmalab - Updates
-
Symbiotec Pharmalab - Updates
-
Symbiotec Pharmalab - Trading Window
-
Symbiotec Pharmalab - Intimation Under Regulation 8(2) Of The Securities And Exchange Board Of India (Prohibition Of Insider
-
Symbiotec Pharmalab - Disclosure Under Regulation 30(5) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations
-
Symbiotec Pharmalab Ltd. debuts with 0.99% discount at Rs 978.20
-
Symbiotec Pharmalab - Listing of Equity Shares of Symbiotec Pharmalab Ltd
-
Symbiotec Pharmalab announces launch of initial public offering
-
Symbiotec Pharma Ltd
Key fundamentals
Evaluate the intrinsic value of Symbiotec Pharmalab Ltd stockÂ
| Name | March-23 | ||||
|---|---|---|---|---|---|
| Assets | 780.079 | ||||
| Liabilities | 780.079 | ||||
| Equity | 10.936 | ||||
| Gross Profit | 79.465 | ||||
| Net Profit | -22.659 | ||||
| Cash From Operating Activities | 93.352 | ||||
| NPM(%) | -4.02 | ||||
| Revenue | 563.586 | ||||
| Expenses | 484.121 | ||||
| ROE(%) | -1.97 |
Corporate Action
| XD-Date | Dividend-Amount | Dividend-% | Dividend Yield(%GE) | Price on that day |
|---|
Peers
Other companies within the same industry or sector that are comparable to Symbiotec Pharmalab Ltd
| Company | Price | Price (% change) | pe(x) | EV/EBITDA(x) | ROE(%) | ROCE(%) |
|---|---|---|---|---|---|---|
| Albert David Ltd | 793.90 | -2.32 | 20.08 | 645.46 | -26.19 | 0.63 |
| Lotus Eye Hospital and Institute Ltd | 113.94 | -0.78 | 1627.71 | 2351.96 | 0.39 | 0.00 |
| Vaishali Pharma Ltd | 7.99 | -1.36 | 24.97 | 14754.60 | 15.42 | 0.00 |
| Astec Lifesciences Ltd | 714.75 | -4.47 | 0.00 | 2519.99 | -363.14 | 0.00 |
Company Info
Our Company wasincorporated as`Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited company, was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025, and a special resolution dated September 12, 2025, passed in the extraordinary general meeting of our Shareholders. Consequently, the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre.Major Events and Milestones:2004- Commenced production of APIs at the Rau Facility2007- Investment by late Rakesh Jhunjhunwala in our Company2009- Received a letter stating that the Rau Facility meets an acceptable state of compliance with cGMP by U.S. FDA2010- Commenced production of APIs including hormone synthesis at the Pithampur Facility- Commissioned a 5 KL biotech plant at the Pithampur Facility- Investment by Franklin Templeton Asset Management (India) Private Limited in our Company2012- Received a letter stating that the Pithampur Facility meets an acceptable state of compliance with the cGMP from the U.S. FDA2013- Investment by Actis Medal Sports Limited in our Company- Commissioned a 35 KL fermentation project at the Pithampur Facility2018- Investment by India Business Excellence Fund- III and Rosewood Investments in our Company2021- Expansion of a sterile plant at the Rau Facility2023- Launched classical fermentation-based APIs at the Pithampur Facility2025- Commissioned a complex injectables facility at the Mhow Facility- Commissioned a 400 KL biomanufacturing facility at the Ujjain Facility
Our Company wasincorporated as`Symbiotec Pharmalab Private Limited' as a private limited company under the Companies Act, 1956, pursuant to a certificate of incorporation dated September 20, 2002, issued by the Registrar of Companies, Madhya Pradesh and Chhattisgarh. Subsequently, in the interest of business expansion and issuing fresh shares to the public to meet requirements of funds for a project being undertaken by the Company which would have resulted into increase in the members of the Company beyond fifty, our Company was converted from a private limited company to a public limited company, pursuant to the Board resolution dated September 22, 2005 and a resolution passed in the extraordinary general meeting of our Shareholders held on October 18, 2005 and the name of our Company was changed to Symbiotec Pharmalab Limited, and a certificate of change of name dated October 27, 2005 was issued to our Company by the Registrar of Companies, Madhya Pradesh & Chhattisgarh. Further, considering the absence of public involvement in the shareholding pattern and the management of the Company, our Company was converted to a private limited company pursuant to the Board resolution dated April 23, 2014 and a resolution passed in the extraordinary general meeting of our Shareholders on May 22, 2014 and the name of our Company was changed to Symbiotec Pharmalab Private Limited and a certificate of incorporation, consequent upon conversion to a private limited company, was issued by the RoC on July 25, 2014. Thereafter, as part of the Company's strategic vision for future growth and expansion, our Company was converted into a public company, pursuant to the Board resolution dated September 11, 2025, and a special resolution dated September 12, 2025, passed in the extraordinary general meeting of our Shareholders. Consequently, the name of our Company was changed to Symbiotec Pharmalab Limited and a fresh certificate of incorporation dated September 26, 2025, consequent upon conversion to a public company, was issued by the Registrar of Companies, Central Processing Centre.Major Events and Milestones:2004- Commenced production of APIs at the Rau Facility2007- Investment by late Rakesh Jhunjhunwala in our Company2009- Received a letter stating that the Rau Facility meets an acceptable state of compliance with cGMP by U.S. FDA2010- Commenced production of APIs including hormone synthesis at the Pithampur Facility- Commissioned a 5 KL biotech plant at the Pithampur Facility- Investment by Franklin Templeton Asset Management (India) Private Limited in our Company2012- Received a letter stating that the Pithampur Facility meets an acceptable state of compliance with the cGMP from the U.S. FDA2013- Investment by Actis Medal Sports Limited in our Company- Commissioned a 35 KL fermentation project at the Pithampur Facility2018- Investment by India Business Excellence Fund- III and Rosewood Investments in our Company2021- Expansion of a sterile plant at the Rau Facility2023- Launched classical fermentation-based APIs at the Pithampur Facility2025- Commissioned a complex injectables facility at the Mhow Facility- Commissioned a 400 KL biomanufacturing facility at the Ujjain Facility
Read More
Parent Organisation
Symbiotec Pharmalab Ltd.
Founded
20/09/2002
Managing Director
Mr.Anil Satwani
NSE Symbol
SYMBIOTECEQ
FAQ
The current price of Symbiotec Pharmalab Ltd is ₹ 1093.80.
The 52-week high for Symbiotec Pharmalab Ltd is ₹ 1143.00 and the 52-week low is ₹ 1080.70.
The market capitalization of Symbiotec Pharmalab Ltd is currently ₹ 7028.33. This value can fluctuate based on stock price movements and changes in the number of shares outstanding.
To buy Symbiotec Pharmalab Ltd shares, you need to have a brokerage account. First, choose a reputable brokerage firm, open an account, and complete the necessary KYC procedures.
To invest in Symbiotec Pharmalab Ltd, you need a brokerage account. After opening an account and completing the KYC process, you can fund your account and use the trading platform to purchase Symbiotec Pharmalab Ltd shares.
The CEO of Symbiotec Pharmalab Ltd is Mr.Anil Satwani, who has been leading the company with a vision to expand its renewable energy portfolio and drive sustainable growth.